Squamous Cell Carcinoma of Head and Neck: all 1,711 studies

Page 9 of 18. Open to participants first (544), then studies with results posted, then the rest; newest registration first within each.

• A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive TractCompletedNCT00894413Phase 2Results posted
• A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and NeckCompletedNCT00756444Phase 2Results posted
• Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck CancerCompletedNCT00736944Phase 2Results posted
• Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck CancerCompletedNCT00671437Phase 2Results posted
• Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx CancerCompletedNCT00665392Phase 2Results posted
• Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT00588770Phase 3Results posted
• Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and NeckTerminatedNCT00570674Phase 1/2Results posted
• Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT00547157Phase 2Results posted
• Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and NeckCompletedNCT00519077Phase 2Results posted
• Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00513435Phase 2Results posted
• Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00507767Phase 2Results posted
• Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerCompletedNCT00492089Phase 2Results posted
• Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and NeckCompletedNCT00459043Phase 2Results posted
• PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of ResponseCompletedNCT00454779Phase 2Results posted
• PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)CompletedNCT00446446Phase 2Results posted
• Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckTerminatedNCT00443261Phase 1Results posted
• Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck CancerCompletedNCT00410826Phase 2Results posted
• Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and NeckTerminatedNCT00392665Phase 2Results posted
• Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00387335Phase 2Results posted
• A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck CancerCompletedNCT00371566Phase 2Results posted
• Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck CancerCompletedNCT00352105Phase 1/2Results posted
• Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)CompletedNCT00343083Phase 2Results posted
• Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or ChemoCompletedNCT00258310Phase 2Results posted
• IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT00229723Phase 2Results posted
• A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck CancerCompletedNCT00210470Phase 2Results posted
• Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and NeckTerminatedNCT00184028Phase 2Results posted
• Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)CompletedNCT00122460Phase 3Results posted
• Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT00103259Phase 2Results posted
• Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and NeckCompletedNCT00096174Phase 2Results posted
• SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00095628Phase 2Results posted
• Zalutumumab in Head and Neck CancerCompletedNCT00093041Phase 1/2Results posted
• Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT00084682Phase 2Results posted
• OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell CancerCompletedNCT00076310Phase 2Results posted
• Intraparenchymal Salivary Gland Corticosteroid Injection to Prevent Radiation-Induced XerostomiaCompletedNCT07802977Phase 1
• Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck CancerActive, not recruitingNCT07791602Phase 2
• Immunohistochemical Expression of Cyclin D1 in Oral Squamous Cell Carcinoma: Relationship With Clinicodemographic and Histopathological FeaturesCompletedNCT07778615
• Taiwanese Green Propolis for Lipid Profiles, Fatigue, and Quality of Life in Oral Cavity Cancer SurvivorsCompletedNCT07682285Not applicable
• Digital Phenotyping of Psychological Distress in Skin Cancer PatientsWithdrawnNCT07670403
• Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)WithdrawnNCT07513324Phase 2
• A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell CarcinomaCompletedNCT07435324Phase 3
• A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell CarcinomaCompletedNCT07435311Phase 1
• Tumor Mutational Burden, Liquid Biopsy, Angiogenic Factors and DCE-MRI Perfusion in HPV-Negative Oropharyngeal CancerActive, not recruitingNCT07407205Not applicable
• Longitudinal Oral Health Changes After Head and Neck RadiotherapyActive, not recruitingNCT07394842
• Optimization of Communication Between Surgery and PathologyCompletedNCT07378345Not applicable
• Collagen Matrix in Oral Cancer SurgeryCompletedNCT07337122
• Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC-SYSU-005）Active, not recruitingNCT07267286Phase 2
• Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT07216833Phase 1
• A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.CompletedNCT07040956Phase 2
• Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and CetuximabCompletedNCT07015333
• A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT07010120Phase 1/2
• A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic MalignanciesTerminatedNCT06974734Phase 1
• EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)Active, not recruitingNCT06923761Phase 1/2
• NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06919666Phase 1/2
• A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)CompletedNCT06894771Phase 1
• A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced CancersTerminatedNCT06870487Phase 1
• Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCCActive, not recruitingNCT06855212Phase 2
• Intratumoral and Peritumoral Habitat Radiomics of MRI Predict Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy in Oral Squamous Cell CarcinomaCompletedNCT06854107
• A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab AloneActive, not recruitingNCT06806852Phase 1
• Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT06790966Phase 3
• Safety and Tolerability of IPH4502 in Patients With Advanced Solid TumorsActive, not recruitingNCT06781983Phase 1
• Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell CarcinomaCompletedNCT06771674
• Thermotherapy for Locally Advanced Head and Neck CancerActive, not recruitingNCT06761937Phase 1
• A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV VirusWithdrawnNCT06741982Phase 1
• ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)CompletedNCT06730412
• Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01Active, not recruitingNCT06727565Phase 2
• Active MMP-8 in Oral Fluid for the Detection of Oral and Oropharyngeal CancerCompletedNCT06701058
• Prognostic Counselling in Palliative Head and Neck Cancer (ProCoPall)Active, not recruitingNCT06699316Not applicable
• Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06673693Phase 2
• A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06668961Phase 2
• Multi-Site Pathological Images-Guided ViT for Oral Squamous Cell Carcinoma Recurrence PredictionCompletedNCT06638762
• Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06630780Not applicable
• Immunohistochemical Expression of EGFR in the Patients Having Oral Squamous Cell CarcinomaCompletedNCT06606301
• Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC)WithdrawnNCT06603155Not applicable
• Can Recurrence of Cancer in the Oropharynx be Detected by Blood Samples?Active, not recruitingNCT06592716
• Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomasActive, not recruitingNCT06557889Phase 2
• A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsCompletedNCT06549816Phase 1
• A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.TerminatedNCT06546553Phase 1
• A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid TumorsActive, not recruitingNCT06544655Phase 1
• A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)Active, not recruitingNCT06525220Phase 3
• A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal CancerWithdrawnNCT06513884Phase 2/3
• AK117 (Anti-CD47 mAb) Plus Cetuximab as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT06508606Phase 2
• A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)Active, not recruitingNCT06496178Phase 3
• Multispectral Optoacoustic Tomography in Head and Neck Squamous Cell CancerSuspendedNCT06477003Not applicable
• PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STSCompletedNCT06413095Early Phase 1
• A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)Active, not recruitingNCT06378177Phase 2
• PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCCCompletedNCT06366451Early Phase 1
• Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx CancerWithdrawnNCT06362421
• ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT06357858Phase 1
• FID-007 Followed by Standard of Care Surgery in Head and Neck CancerTerminatedNCT06338657Phase 1
• FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06332092Phase 2
• Ex Vivo 3D-ultrasound for Oropharyngeal CancerCompletedNCT06314711Not applicable
• Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06308913Early Phase 1
• Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant NeoplasmsCompletedNCT06307093Phase 1
• A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid TumoursActive, not recruitingNCT06305247Phase 1/2
• INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCCActive, not recruitingNCT06295731Phase 2/3
• Heavy Strength Training in Head and Neck Cancer SurvivorsCompletedNCT06289049Phase 2
• A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid TumorsTerminatedNCT06285097Phase 1
• A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid TumorsCompletedNCT06273852Early Phase 1
• Oral Cavity Squamous Cell Carcinoma and Readmission: Rates, Causes, and Risk Factors.CompletedNCT06259838
• A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing RadiotherapyCompletedNCT06251050Phase 1/2

← Squamous Cell Carcinoma of Head and Neck overview